The vaccine is also 86 percent effective, according to the press release. against a more infectious variant of the coronavirus that was discovered in the UK. On the other hand, in South Africa, the effectiveness of the preparation was found at the level of 55%.
The company emphasizes that in both studies, both in the UK and South Africa, the vaccine was 100 percent. effective in preventing severe COVID-19 symptoms and death from the disease.
According to Novavax Inc. The results of the final analysis of the study in the UK were largely in line with interim figures, released in January, which also showed that the vaccine is 96 percent. effective against the original version of the coronavirus and around 86% for the British variant.
Phase 3 clinical trials were conducted in the UK on over 15,000 people aged 18 to 84, of which 27 percent. were over 65. In South Africa, 2,665 people took part in the research.
The American company expects to use this data to apply for approval for use in various countries. It is unclear when she will apply for authorization in the US, or whether regulators will require her to complete the ongoing US research process.
The two-dose preparation of Novavax is fundamentally different from the vector and mRNA vaccines already approved for use in the world. It is a recombinant subunit vaccine, i.e. a vaccine containing a virus protein against which antibodies are produced
We are glad that you are with us. Subscribe to the Onet newsletter to receive the most valuable content from us
Source: PAP
Creation date: 12 mark 2021, 02:59
–
